Bioretec Ltd Makes Significant Adjustments to Stock Options Following Rights Issue Completion
Bioretec Ltd Adjusts Stock Option Terms
On June 27, 2025, Bioretec Ltd, a Finnish medical device company, released an announcement detailing changes to its stock option programs due to the completion of a rights issue. This move aims to uphold fairness for holders of stock options following the subscription of 6,156,618 new shares by investors.
Rights Issue Completion
The rights issue, known as the "Offering," was successfully concluded, with new shares registered under the Finnish Patent and Registration Office on June 26, 2025. This strategic financial maneuver is a response to the need for Bioretec to enhance equity and maintain trust among its investors by ensuring equal treatment between shareholders and option holders.
Adjustments to Stock Options
To achieve fairness, the Board of Directors at Bioretec has determined that adjustments to the stock option terms are necessary. Under current conditions, if the company issues additional shares before option holders subscribe, those holding options must be treated comparably to existing shareholders. This process includes adjusting the subscription prices of new shares under the existing option programs.
The revised subscription prices for the programs are as follows:
| Stock Option Program | Prior Subscription Price (EUR) | New Subscription Price (EUR) |
|---|---|---|
| ----- | -------- | -------- |
| 2018-1A | 1.50 | 1.42 |
| 2018-1B | 1.50 | 1.42 |
| 2018-1C | 2.25 | 2.13 |
| 2018-1D | 2.25 | 2.13 |
| 2020-1A | 2.25 | 2.13 |
| 2020-1B | 3.00 | 2.84 |
| 2020-1C | 3.75 | 3.55 |
| 2023-1 | 2.48 | 2.35 |
| 2025-1 | 2.79 | 2.64 |
| 2025-2 | 2.79 | 2.64 |
Bioretec’s Strategic Vision
Bioretec Ltd specializes in developing biodegradable orthopedic implants, with a focus on enhancing surgical outcomes and promoting healing. Their leading product line, RemeOs™, utilizes a magnesium alloy and hybrid composites. This innovative approach aims to eliminate the need for removal surgeries associated with traditional implants, supporting better recovery results for patients. The RemeOs™ series has received significant approvals, including CE marking in January 2025 and U.S. authorization in March 2023, positioning Bioretec to expand into the lucrative orthopedic trauma and spine market, projected at over USD 10 billion.
The adjustments to the stock option programs reflect Bioretec's dedication to maintaining strong relationships with its investors while fostering an environment that emphasizes equality and growth. As the company moves forward, it remains committed to pioneering medical advancements that benefit both patients and healthcare providers alike.
For further inquiries, stakeholders can reach out to Sarah van Hellenberg Hubar-Fisher (Interim CEO) at +31 6 1544 8736, or Johanna Salko (CFO) at +358 40 754 8172.
For more information about Bioretec and its initiatives, visit www.bioretec.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.